Name
GP2 Human
Cat. No.
MAG-6214
Tag/Conjugates
His
Source
Sf9 insect cells.
Shipped
Shipped with Ice Packs
Description
GP2 is a cDNA coding for the free form of the human pancreatic secretory granule membrane major glycoprotein / GP2 having a molecular mass of 68,000 Dalton (protein component excluding glycosylation; observed molecular weight approx. 68 kDa) pH 5.4. GP2 protein is fused to a deca-histidine purification tag.
Synonyms
Glycoprotein 2 (zymogen granule membrane), Pancreatic zymogen granule membrane protein GP-2, ZAP75, DKFZp779K0533.
Introduction
Crohn's Disease (CD), which is very common in Caucasians, is an inflammatory bowel diseases (IBD). Mucosal inflammation in CD seems to arise when dysregulation of the immune system breaks the balance between tolerance to commensal microbiota or food-derived antigens and immunity to pathogens. The autoimmune mechanisms takes part in the development of CD, and exocrine pancreas autoantibodies (PAB) are disease-specific in CD patients. It was established not too long ago that glycoprotein 2 (GP2) is the major autoantigenic mark recognized by CD-specific PAB. Furthermore to IgG and IgM PAB isotypes, IgA pancreatic autoantibodies were also identified in CD patients. GP2 is an extremely glycosylated 78 kDa protein with N-linked carbohydrates. It is responsible for up to 40% of all zymogen granule (ZG) membrane proteins in pancreatic acinar cells and is linked to the ZG membrane via a glycosyl phosphoinositol (GPI) anchor.
Physical Appearance
/
Formulation
GP2 solution is supplied in 16mM HEPES buffer pH-7.5, 80mM NaCl and 20% glycerol.
Stability
Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. Avoid multiple freeze-thaw cycles.
Purity
Greater than 95% as determined by SDS-PAGE.
Amino acid sequence
/
Safety Data Sheet
SDS
Usage
Mabioway's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
